Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Left ventricular hypertrophy is a leading risk factor for cardiovascular morbidity and mortality.
Although reverse ventricular remodelling was long thought to be irreversible, evidence from …

2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American
College of Cardiology Foundation/American Heart Association Task Force on Practice …

Objectives: This randomized controlled multicenter trial evaluated coenzyme Q10 (CoQ10)
as adjunctive treatment in chronic heart failure (HF). Background: CoQ10 is an essential …

It is important that the medical profession play a significant role in critically evaluating the
use of diagnostic procedures and therapies as they are introduced and tested in the …

Background Previous studies have suggested that cardiac resynchronization achieved
through atrial-synchronized biventricular pacing produces clinical benefits in patients with …

Cardiac remodeling is generally accepted as a determinant of the clinical course of heart
failure (HF). Defined as genome expression resulting in molecular, cellular and interstitial …

Heart failure (HF) is a major and growing public health problem in the United States.
Approximately 5 million patients in this country have HF, and over 550 000 patients are …

OBJECTIVES To create a valid, sensitive, disease-specific health status measure for
patients with congestive heart failure (CHF). BACKGROUND Quantifying health status is …

Background—Treatments that reduce mortality and morbidity in patients with heart failure
with reduced ejection fraction, including angiotensin-converting enzyme inhibitors (ACEI) …